10]. GOLD highlights that COPD patients should follow infection control measures to prevent infection with SARS-CoV-2, including social distancing and hand-washing [14]. GOLD also recommends COVID-19 vaccination according to national guidelines and mask-wearing when there is a high community...
Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollutiondoi:10.12659/MSM.942672Parums, Dinah V.Medical Science Monitor
基于2023版GOLD指南,建议50~80岁、有20包/年吸烟史、目前吸烟或在过去15年内戒烟的成年人每年接受一次LDCT肺癌筛查。但是,对于戒烟超过15年、或有严重影响预期寿命的健康问题、或有能力或意愿接受治愈性肺部手术的患者,应停止筛查。对于从不吸烟的COPD患者,不建议每年开展LDCT筛查,因为筛查的潜在危害似乎大于发现早期肺...
GOLD 推荐的 COPD 治疗药品有 46 种,其中 38 种在我 国上市.相较于国内临床治疗指南而言,GOLD 多收录 了 1 种 COPD 三联复合制剂——倍氯米松/福莫特罗/格 隆溴铵(倍氯福格),但 GOLD 收录的祛痰药及抗氧化剂 种类较少.国家医保目录共覆盖 COPD 治疗药品 46 种, 三联复合制剂在 2023 年被首次纳入医保...
基于2023版GOLD指南,建议50~80岁、有20包/年吸烟史、目前吸烟或在过去15年内戒烟的成年人每年接受一次LDCT肺癌筛查。但是,对于戒烟超过15年、或有严重影响预期寿命的健康问题、或有能力或意愿接受治愈性肺部手术的患者,应停止筛查。对于...
考虑外科手术GOLDExecutiveCommittee.Guidelines:Globalstrategyforthediagnosis,management,andpreventionofchronicobstructivepulmonarydisease.(UPDATED2023)COPD急性加重期(AECOPD)COPD急性加重定义是指在COPD自然病程中发生旳事件,特征为患者旳基线呼吸困难、咳嗽和/或咳痰变化超出日常旳波动范围,为急性发作,可能需要变化常规药物...
The objective of this study was to evaluate Swiss primary practitioners' adherence to the GOLD guidelines for the pharmacological treatment of stable COPD. (2) Methods: We studied patients who were included in the Swiss COPD cohort study, an ongoing prospective study in a primary care setting, ...
2023, Respiratory Medicine Citation Excerpt : Although Chinese guidelines are similar to GOLD, guidelines for Australia, Japan, and Korea use a step-wise approach to optimize pharmacotherapy for stable COPD, and state that when monotherapy is not sufficiently successful then combination LABA/LAMA treatm...
A gap exists between guidelines and real-world clinical practice for the management and treatment of chronic obstructive pulmonary disease (COPD). Although this has narrowed in the last decade, there is room for improvement in detection rates, treatment
In 2023, GOLD proposed a further evolution of the ABCD assessment tool, recognizing the clinical relevance of ECOPD independently of the level of symptoms (GOLD ABE assessment tool).4 In both assessment tools, ECOPD history is divided into moderate ECOPD (ie, events treated with bronchodilators...